Now there's safe, effective relief for innocents abroad

June 21, 2004

News

Article

Clinicians can now offer their patients the first nonsystemic, gastrointestinal selective antibiotic to receive FDA approval. The agency recently approved rifaximin (Xifaxan, Salix Pharmaceuticals) tablets for the treatment of TD caused by noninvasive strains of Escherichia coli in those 12 years of age or older. Rifaximin is currently approved for use in 17 countries worldwide. It is expected to be available in U.S. pharmacies in August.

Related Content

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara

November 12th 2024

Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff

August 6th 2020

Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia

Lauren Biscaldi, MS, Managing Editor

November 5th 2024

Article

The drug is also approved to treat schizophrenia and bipolar depression.

FDA Approves Journey Medical’s Emrosi for Rosacea

Lauren Massaro

November 5th 2024

Article

“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.

FDA Expands OA REMS, Mandates Mail-Back Envelopes for Opioid Analgesics

Lauren Massaro

November 4th 2024

Article

The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.